摘要
血清素(5-羟色胺,5-HT)是一种生物单胺,作为中枢神经中的神经递质,在肠道中的局部介质和血液中的血管活性剂。血清素通过与耦合到各种信号通路的多个受体的相互作用来发挥其多种作用,有时候是相反的作用。除了它众所周知的功能,血清素已被证明是一个对广泛的正常和癌症细胞的促有丝分裂因子。血清素对侵袭性癌症和类癌往往通过5- HT1和5-HT2受体展现出增殖刺激作用。相反,低剂量的血清素能通过减少血流供应来抑制肿瘤生长,表明血清素对肿瘤的生长作用是浓度依赖性的。研究数据也同样适用于血清素对于肿瘤细胞的迁移,转移过程及血管生成的调节。此外,某些肿瘤的发展伴随着血清素受体表达模式的失调。血清中的血清素水平被发现适用于膀胱上的尿路上皮癌,前列腺癌和肾细胞癌的预后评估。在某些情况下,血清素受体拮抗剂,血清素合成的选择性血清素转运拮抗剂已成功的运用与阻止癌症细胞生长。该综述再评价了血清素对几种类型癌症及在其病程的不同阶段的参与。
关键词: 血管新生,癌变,良性肿瘤的,癌,化疗,神经内分泌细胞,血清素,癌症抑制。
Current Molecular Medicine
Title:Serotonin and Cancer: What Is the Link?
Volume: 15 Issue: 1
Author(s): D. Sarrouilhe, J. Clarhaut, N. Defamie and M. Mesnil
Affiliation:
关键词: 血管新生,癌变,良性肿瘤的,癌,化疗,神经内分泌细胞,血清素,癌症抑制。
摘要: Serotonin (5-hydroxytryptamine, 5-HT) is a biogenic monoamine that acts as a neurotransmitter in the central nervous system, local mediator in the gut and vasoactive agent in the blood. Serotonin exerts its multiple, sometimes opposing actions through interaction with a multiplicity of receptors coupled to various signalling pathways. In addition to its well-known functions, serotonin has been shown to be a mitogenic factor for a wide range of normal and tumoral cells. Serotonin exhibits a growth stimulatory effect in aggressive cancers and carcinoids more often through 5- HT1 and 5-HT2 receptors. In contrast, low doses of serotonin can inhibit tumour growth via the decrease of blood supply to the tumour, suggesting that the role of serotonin on tumour growth is concentration-dependent. Data are also available on serotonin involvement in cancer cell migration, metastatic processes and as a mediator of angiogenesis. Moreover, the progression of some tumours is accompanied by a dysregulation of the pattern of serotonin receptor expressions. Serum serotonin level was found to be suitable for prognosis evaluation of urothelial carcinoma in the urinary bladder, adenocarcinoma of the prostate and renal cell carcinoma. In some cases, antagonists of serotonin receptors, inhibitors of selective serotonin transporter and of serotonin synthesis have been successfully used to prevent cancer cell growth. This review revaluates serotonin involvement in several types of cancer and at different stages of their progression.
Export Options
About this article
Cite this article as:
D. Sarrouilhe, J. Clarhaut, N. Defamie and M. Mesnil , Serotonin and Cancer: What Is the Link?, Current Molecular Medicine 2015; 15 (1) . https://dx.doi.org/10.2174/1566524015666150114113411
DOI https://dx.doi.org/10.2174/1566524015666150114113411 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Biological Evaluation and In Silico Study of β-Chloro Vinyl Chalcones as Inhibitors of the TNF-α, IL-6 With Anticancer and Antioxidant Activity
Letters in Drug Design & Discovery Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Current Drug Targets Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism 2-(4-Aminophenyl) Benzothiazole: A Potent and Selective Pharmacophore with Novel Mechanistic Action Towards Various Tumour Cell Lines
Mini-Reviews in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Assessment of the Physicochemical Properties and Stability for Pharmacokinetic Prediction of Pyrazinoic Acid Derivatives
Current Drug Metabolism Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Recent Advances in Efficacy of using Doxorubicin Gold Nanoparticles for Chemo-, Radio-, Photothermal, and Photodynamic Therapy
Current Drug Delivery Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs
Current Pharmaceutical Design MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology